<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nafarelin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nafarelin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nafarelin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11505" href="/d/html/11505.html" rel="external">see "Nafarelin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F199096"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Synarel</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867627"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Synarel</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F199127"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin Releasing Hormone Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F199099"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Endometriosis:</b>
<b>Intranasal:</b> One spray (200 mcg) into 1 nostril each morning and 1 spray (200 mcg) into the other nostril each evening starting between days 2 and 4 of menstrual cycle (total: 2 sprays [400 mcg] daily). If regular menstruation persists after 2 months of therapy, may increase dose to 2 sprays (400 mcg; 1 spray in each nostril) in the morning and evening (total: 4 sprays [800 mcg] daily). Total duration of therapy should not exceed 6 months due to decreases in bone mineral density; retreatment is not recommended by the manufacturer.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989987"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987344"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F199100"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F199114"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bd49784-37fe-43fb-bf63-92207c0b2eef">Central precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty:</b> Intranasal: Males/Females: (US labeling): Two sprays (400 mcg) into each nostril in the morning and 2 sprays (400 mcg) into each nostril in the evening (total: 8 sprays [1,600 mcg] daily). If inadequate suppression, may increase dose to 3 sprays (600 mcg) into alternating nostrils 3 times daily (total: 9 sprays [1,800 mcg] daily). Continue therapy until resumption of puberty is desired.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130406"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51130407"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F199077"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Reported adverse reactions are for children and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acne vulgaris (10%), body odor (4%), hypertrichosis (transient, pubic region: 5%), seborrhea (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hot flashes (3%; transient)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Breast hypertrophy (8%; transient), vaginal discharge (3%), vaginal hemorrhage (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Emotional lability (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Rhinitis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acne vulgaris (14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased libido (23%), decreased serum calcium (10% to 15%), hot flash (90%), increased serum phosphate (10% to 15%), increased serum triglycerides (12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Vaginal dryness (19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Decreased white blood cell count (10% to 15%), eosinophilia (10% to 15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Emotional lability (16%), headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Edema (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Seborrhea (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hirsutism (3%), increased libido (2%), increased serum cholesterol (6%), weight gain (8%), weight loss (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Breast atrophy (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Depression (3%), insomnia (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Myalgia (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasal mucosa irritation (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Palpitations</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Chloasma, maculopapular rash</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Breast engorgement, lactation</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia, paresthesia</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Eye pain</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined: Neuromuscular &amp; skeletal: Decreased bone mineral density</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, arterial thromboembolism, venous thromboembolism (including deep vein thrombosis and pulmonary embolism)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian cyst</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, intracranial hypertension (idiopathic), seizure, suicidal ideation, suicidal tendencies, transient ischemic attacks</p></div>
<div class="block coi drugH1Div" id="F199087"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, or any component of the formulation; undiagnosed abnormal vaginal bleeding; pregnant patients or those who may become pregnant; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F199074"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone density: Has been reported and may be irreversible. Use with caution in patients with risk factors for bone loss (eg, chronic alcohol use, antiseizure or corticosteroid therapy, family history of osteoporosis). Repeat courses are not recommended in patients with major risk factors for bone loss.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cysts: May occur within the first 2 months of therapy and may occur more commonly in patients with polycystic ovarian disease. These cysts may resolve spontaneously, generally by about 4 to 6 weeks of therapy, but sometimes require discontinuation of therapy and/or surgical intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported in pediatric patients receiving GnRH agonists, including nafarelin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric events: Emotional lability, such as crying, irritability, impatience, anger, and aggression, has been reported in patients taking GnRH agonists. Depression, including rare reports of suicidal ideation and attempt, has been reported for GnRH agonists in children treated for CPP; many of these patients had a history of psychiatric illness or other comorbidities with an increased risk of depression. Depression may also occur or worsen in patients being treated for endometriosis. Monitor for development or worsening of psychiatric symptoms, including depression, during treatment; consider referral to a mental health professional in patients with new or worsening depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Have been observed in patients receiving GnRH agonists; patients with a history of seizures, cerebrovascular disorders, CNS anomalies/tumors, and patients on concomitant medications that have been associated with seizures are at increased risk; has also been reported in patients without risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CPP use: When used for the treatment of CPP, some signs of puberty (eg vaginal bleeding, breast enlargement) may occur but should resolve within the first 2 months of therapy.</p></div>
<div class="block dosfc drugH1Div" id="F51558384"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Synarel 8 mL bottles contain at least 60 sprays.</p></div>
<div class="block foc drugH1Div" id="F199083"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synarel: 2 mg/mL (8 mL)</p></div>
<div class="block geq drugH1Div" id="F199070"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F199089"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Synarel Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $453.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867628"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synarel: 2 mg/mL (8 mL) [contains benzalkonium chloride]</p></div>
<div class="block adm drugH1Div" id="F803173"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal: </b>Nasal spray: Prior to initial use, prime pump by releasing 7 to 10 sprays until a fine spray is released. After priming, hold the bottle horizontal and run spray tip under warm water for 15 seconds while wiping with finger or soft cloth; dry tip with tissue or soft cloth. Repeat this cleaning procedure before and after each use to prevent tip from clogging; do not clean spray tip using a pointed object. Blow nose gently to clear nostrils before use. Allow ~30 seconds to elapse between sprays. Sneezing during or immediately after dosing should be avoided (may decrease drug absorption). Do not use a topical nasal decongestant for at least 2 hours (US labeling) or at least 30 minutes (Canadian labeling) after nafarelin use.</p></div>
<div class="block admp drugH1Div" id="F52613381"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal: Nasal spray: Prior to initial use, prime pump by releasing 7 to 10 sprays until a fine spray is released; after priming, hold the bottle horizontal and run spray tip under warm water for 15 seconds while wiping with finger or soft cloth; dry tip with tissue or soft cloth. Repeat this cleaning procedure before and after each use to prevent tip from clogging; do not clean spray tip using a pointed object. Blow nose gently to clear nostrils before use. Insert tip into nostril, aim tip toward the back and outer side of nose and close off the other nostril. Administer nasal spray while inhaling; allow ~30 seconds to elapse between sprays. Sneezing during or immediately after dosing should be avoided (may decrease drug absorption). Do not use a topical nasal decongestant for at least 2 hours following nafarelin use.</p></div>
<div class="block hazard drugH1Div" id="F49132669"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block meg drugH1Div" id="F50184180"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Synarel: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F019886s039lbl.pdf%23page%3D28&amp;token=OfntyV3iVTRwIcoAjj6wO6Pqc3jL2opF6UctqBw%2BEd1XmatSFjbmhuizYwj04KI%2FVMDu%2FQAHdAU17UxzQWF3XiUmCakXilW7qD82r5xN41D5ALkCn449PvWlVP%2FVCvS8&amp;TOPIC_ID=9673" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019886s039lbl.pdf#page=28</a></p></div>
<div class="block use drugH1Div" id="F199084"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty:</b> Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b> Management of endometriosis, including pain relief and reduction of endometriotic lesions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limitations of use: </i>Treatment for endometriosis is limited to patients ≥18 years of age treated for 6 months.</p></div>
<div class="block mst drugH1Div" id="F199133"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nafarelin may be confused with Anafranil, enalapril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299735"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F199078"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Flotufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of ADT on the performance of flotufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Androgen Deprivation Therapy Agents may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact of ADT on the performance of gallium Ga 68 PSMA-11 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Piflufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of ADT on the performance of piflufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308485"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Exclude pregnancy prior to use. Use is contraindicated in patients who may become pregnant during therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Ovulation is inhibited and menstruation is stopped when used appropriately for the treatment of endometriosis; however, contraception is not assured. Nonhormonal contraception is recommended. Breakthrough bleeding or ovulation may occur if successive doses are missed. There is no evidence that pregnancy rates are enhanced or adversely affected by use.</p></div>
<div class="block pri drugH1Div" id="F2929271"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F20616394"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if nafarelin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Use in patients who are breastfeeding is contraindicated.</p></div>
<div class="block mop drugH1Div" id="F2929987"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CPP: Bone mineral density (BMD), GnRH testing (blood LH and FSH levels), measurement of bone age, Tanner staging; monitor for development or worsening of psychiatric symptoms, including depression; signs/symptoms of pseudotumor cerebri.</p>
<p style="text-indent:-2em;margin-left:2em;">Endometriosis: Menstruation, vaginal bleeding or spotting which persists after 2 months of treatment. BMD if retreatment is considered following a 6-month course of therapy. Signs and symptoms of depression.</p></div>
<div class="block pha drugH1Div" id="F199073"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potent synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH; LHRH) which is approximately 200 times more potent than GnRH in terms of pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Effects on the pituitary gland and sex hormones are dependent upon its length of administration. After acute administration, an initial stimulation of the release of LH and FSH from the pituitary is observed; an increase in androgens and estrogens subsequently follows. Continued administration of nafarelin, however, suppresses gonadotrope responsiveness to endogenous GnRH resulting in reduced secretion of LH and FSH and, secondarily, decreased ovarian and testicular steroid production.</p></div>
<div class="block phk drugH1Div" id="F199086"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: ~80%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Degraded by peptidase; forms metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~1% to 6%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~3 hours; Metabolites: ~86 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 10 to 45 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (44% to 55%, ~3% as unchanged drug); feces (19% to 44%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F199090"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Synrelin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Synrelina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Synarel | Synarela</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Synarela</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nafarelin Dci | Synarel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Nasarel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nafarelil | Nasanyl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Synarela</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Synarela</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Synarel | Synarela</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Synarel | Synarela</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Synarel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9176437">
<a name="9176437"></a>Hornstein MD, Yuzpe AA, Burry K, et al. Retreatment With Nafarelin for Recurrent Endometriosis Symptoms: Efficacy, Safety and Bone Mineral Density. <i>Fertil Steril</i>. 1997;67(6):1013-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafarelin-drug-information/abstract-text/9176437/pubmed" id="9176437" target="_blank">9176437</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Synarel (nafarelin) [prescribing information]. New York, NY: Pfizer; January 2023.</div>
</li>
<li>
<div class="reference">
                  Synarel (nafarelin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10731543">
<a name="10731543"></a>Tahara M, Matsuoka T, Yokoi T, et al. Treatment of Endometriosis With a Decreasing Dosage of a Gonadotropin-Releasing Hormone Agonist (Nafarelin): A Pilot Study With Low-Dose Agonist Therapy (“Draw-Back” Therapy). <i>Fertil Steril</i>. 2000;73(4):799-804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nafarelin-drug-information/abstract-text/10731543/pubmed" id="10731543" target="_blank">10731543</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9673 Version 164.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
